Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

A phase II study of S-1 in relapsed small cell lung cancer.

Kudo K, Ohyanagi F, Horiike A, Miyauchi E, Tahanaka H, Yanagitani N, Saito R, Kaburaki K, Sakatani T, Horai T, Nishio M.

Mol Clin Oncol. 2013 Mar;1(2):263-266. Epub 2013 Jan 14.

2.

Phase II trial of vinflunine in relapsed small cell lung cancer.

Spigel DR, Hainsworth JD, Lane CM, Clark B, Burris HA, Greco FA.

J Thorac Oncol. 2010 Jun;5(6):874-8.

3.

Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group Trial 1597.

Masters GA, Declerck L, Blanke C, Sandler A, DeVore R, Miller K, Johnson D; Eastern Cooperative Oncology Group.

J Clin Oncol. 2003 Apr 15;21(8):1550-5.

PMID:
12697880
4.

A phase II study of higher dose weekly topotecan in relapsed small-cell lung cancer.

Spigel DR, Greco FA, Burris HA 3rd, Shipley DL, Clark BL, Whorf RC, Arrowsmith ER, Hainsworth JD.

Clin Lung Cancer. 2011 May;12(3):187-91. doi: 10.1016/j.cllc.2011.03.016. Epub 2011 Apr 28.

PMID:
21663862
5.

Phase II trial of amrubicin and carboplatin in patients with sensitive or refractory relapsed small-cell lung cancer.

Hirose T, Nakashima M, Shirai T, Kusumoto S, Sugiyama T, Yamaoka T, Okuda K, Ohnishi T, Ohmori T, Adachi M.

Lung Cancer. 2011 Sep;73(3):345-50. doi: 10.1016/j.lungcan.2010.12.015. Epub 2011 Jan 31.

PMID:
21277039
6.

Phase-II trial of rebeccamycin analog, a dual topoisomerase-I and -II inhibitor, in relapsed "sensitive" small cell lung cancer.

Schwandt A, Mekhail T, Halmos B, O'Brien T, Ma PC, Fu P, Ivy P, Dowlati A.

J Thorac Oncol. 2012 Apr;7(4):751-4. doi: 10.1097/JTO.0b013e31824abca2.

7.

Phase II study of second-line gemcitabine in sensitive or refractory small cell lung cancer.

Hoang T, Kim K, Jaslowski A, Koch P, Beatty P, McGovern J, Quisumbing M, Shapiro G, Witte R, Schiller JH.

Lung Cancer. 2003 Oct;42(1):97-102.

PMID:
14512193
8.

Paclitaxel plus bevacizumab in patients with chemoresistant relapsed small cell lung cancer as salvage treatment: a phase II multicenter study of the Hellenic Oncology Research Group.

Mountzios G, Emmanouilidis C, Vardakis N, Kontopodis E, Hatzidaki D, Popis E, Karachaliou N, Kotsakis A, Agelidou M, Georgoulias V.

Lung Cancer. 2012 Jul;77(1):146-50. doi: 10.1016/j.lungcan.2012.02.002. Epub 2012 Mar 13.

PMID:
22418242
9.

Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301.

Onoda S, Masuda N, Seto T, Eguchi K, Takiguchi Y, Isobe H, Okamoto H, Ogura T, Yokoyama A, Seki N, Asaka-Amano Y, Harada M, Tagawa A, Kunikane H, Yokoba M, Uematsu K, Kuriyama T, Kuroiwa Y, Watanabe K; Thoracic Oncology Research Group Study 0301.

J Clin Oncol. 2006 Dec 1;24(34):5448-53.

PMID:
17135647
10.

Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers: a Hoosier Oncology Group phase II trial.

Moore AM, Einhorn LH, Estes D, Govindan R, Axelson J, Vinson J, Breen TE, Yu M, Hanna NH.

Lung Cancer. 2006 Apr;52(1):93-7. Epub 2006 Feb 20.

PMID:
16488055
11.

Paclitaxel plus bevacizumab in patients with chemosensitive relapsed small cell lung cancer: a safety, feasibility, and efficacy study from the Hoosier Oncology Group.

Jalal S, Bedano P, Einhorn L, Bhatia S, Ansari R, Bechar N, Koneru K, Govindan R, Wu J, Yu M, Schneider B, Hanna N.

J Thorac Oncol. 2010 Dec;5(12):2008-11. doi: 10.1097/JTO.0b013e3181f77b6e.

12.

Phase II study of amrubicin combined with carboplatin for refractory relapsed small-cell lung cancer: North Japan Lung Cancer Group Trial 0802.

Kawashima Y, Inoue A, Sugawara S, Oizumi S, Maemondo M, Okudera K, Suzuki T, Usui K, Harada M, Morikawa N, Hasegawa Y, Saito R, Ishimoto O, Sakakibara T, Asahina H, Nukiwa T.

Respir Investig. 2014 May;52(3):190-4. doi: 10.1016/j.resinv.2013.12.005. Epub 2014 Jan 28.

PMID:
24853020
13.

Phase II study of paclitaxel, ifosfamide, and cisplatin as second-line treatment in relapsed small-cell lung cancer.

Kosmas C, Tsavaris NB, Malamos NA, Vadiaka M, Koufos C.

J Clin Oncol. 2001 Jan 1;19(1):119-26.

PMID:
11134204
14.

Combination chemotherapy with irinotecan and cisplatin in elderly patients (>or= 65 years) with extensive-disease small-cell lung cancer.

Kim HG, Lee GW, Kang JH, Kang MH, Hwang IG, Kim SH, Hahm JR, Jeong YY, Kim HC, Lee JD, Lee JS, Hwang YS.

Lung Cancer. 2008 Aug;61(2):220-6. doi: 10.1016/j.lungcan.2007.12.020. Epub 2008 Feb 12.

PMID:
18272249
15.

A phase I study of amrubicin and fixed dose of irinotecan (CPT-11) in relapsed small cell lung cancer: Japan multinational trial organization LC0303.

Kawahara M, Kubo A, Komuta K, Fujita Y, Sasaki Y, Fukushima M, Daimon T, Furuse K, Mishima M, Mio T.

J Thorac Oncol. 2012 Dec;7(12):1845-9.

16.

Ifosfamide-based chemotherapy for previously treated lung cancer patients.

Chen YM, Liu JM, Wu MF, Wu HW, Lin WC, Tsai CM, Perng RP, Whang-Peng J.

Zhonghua Yi Xue Za Zhi (Taipei). 1998 Jul;61(7):389-96.

PMID:
9699391
17.

S-1 plus cisplatin with concurrent radiotherapy for locally advanced non-small cell lung cancer: a multi-institutional phase II trial (West Japan Thoracic Oncology Group 3706).

Ichinose Y, Seto T, Sasaki T, Yamanaka T, Okamoto I, Takeda K, Tanaka M, Katakami N, Sawa T, Kudoh S, Saka H, Nishimura Y, Nakagawa K, Fukuoka M.

J Thorac Oncol. 2011 Dec;6(12):2069-75. doi: 10.1097/JTO.0b013e3182307e5a.

18.

Randomized comparison of early versus late hyperfractionated thoracic irradiation concurrently with chemotherapy in limited disease small-cell lung cancer: a randomized phase II study of the Hellenic Cooperative Oncology Group (HeCOG).

Skarlos DV, Samantas E, Briassoulis E, Panoussaki E, Pavlidis N, Kalofonos HP, Kardamakis D, Tsiakopoulos E, Kosmidis P, Tsavdaridis D, Tzitzikas J, Tsekeris P, Kouvatseas G, Zamboglou N, Fountzilas G.

Ann Oncol. 2001 Sep;12(9):1231-8.

PMID:
11697833
19.

Pemetrexed in relapsed small-cell lung cancer and the impact of shortened vitamin supplementation lead-in time: results of a phase II trial.

Socinski MA, Raju RN, Neubauer M, Smith DA, Richards DA, Savin M, Ruxer RL, Reynolds CH, Zhan F, Bromund JL, Chen R, Obasaju C.

J Thorac Oncol. 2008 Nov;3(11):1308-16. doi: 10.1097/JTO.0b013e3181898e32.

20.

Cisplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in untreated patients with extensive-stage small cell lung cancer: a phase II trial of the Southwest Oncology Group.

Kelly K, Lovato L, Bunn PA Jr, Livingston RB, Zangmeister J, Taylor SA, Roychowdhury D, Crowley JJ, Gandara DR; Southwest Oncology Group.

Clin Cancer Res. 2001 Aug;7(8):2325-9.

Supplemental Content

Support Center